BREAKING NEWS: Apotex appeals Preliminary Injunction Order to Federal Circuit - Big Molecule Watch

As we covered yesterday, the district court issued an order in Amgen v. Apotex granting Amgen a preliminary injunction that would prohibit Apotex from launching its biosimilar pegfilgrastim product until 180 days after it receives FDA approval and gives notice of commercial marketing. Today, Apotex filed a notice of appeal of that order to the Federal Circuit. The notice of appeal is available here.

Stay tuned for further updates and analysis.

Download PDF